Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: Pharmacophore-based virtual screening, synthesis, and pharmacology

Journal of Medicinal Chemistry

Volumn 53, Issue 17, 2010, Pages 6490-6505

  Chaudhaery, Shailendra S ^a   Roy, Kuldeep K ^a   Shakya, Neeraj ^a   Saxena, Gunjan ^a   Sammi, Shreesh Raj ^a   Nazir, Aamir ^a   Nath, Chandishwar ^a   Saxena, Anil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(3 FLUORO 4 PYRIDINYL)AMINO] 3 METHYL 1H INDOL 5 YL METHYLCARBAMATE; 2 CHLOROPHENYLCARBAMIC ACID 1 BENZYL 1,2,3,4 TETRAHYDROQUINOLIN 6 YL ESTER; 2 CHLOROPHENYLCARBAMIC ACID QUINOLIN 6 YL ESTER; 3 BROMOPHENYLCARBAMIC ACID 1,2,3,4 TETRAHYDROQUINOLIN 6 YL ESTER; 4 BROMOPHENYLCARBAMIC ACID 1,2,3,4 TETRAHYDROQUINOLIN 6 YL ESTER; 4 BROMOPHENYLCARBAMIC ACID 1-METHYL-1,2,3,4-TETRAHYDROTETRAHYDROQUINOLIN 6 YL ESTER; 4 CHLORO 3 TRIFLUOROMETHYLPHENYLCARBAMIC ACID 1 METHYL 1,2,3,4 TETRAHYDROQUINOLIN 6 YL ESTER; 4 CHLORO 3 TRIFLUOROMETHYLPHENYLCARBAMIC ACID 1,2,3,4 TETRAHYDROQUINOLIN 6 YL ESTER; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GANSTIGMINE; HEPTYLSTIGMINE TARTRATE; HEXYLCARBAMIC ACID 1 BENZYL 1,2,3,4 TETRAHYDROQUINOLIN 6 YL ESTER; N HEPTYLCARBAMIC ACID QUINOLIN 6 YL ESTER; PHENSERINE; PHYSOSTIGMINE; QUILOSTIGMINE; RIVASTIGMINE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; ANIMALS; AVOIDANCE LEARNING; CAENORHABDITIS ELEGANS; CARBAMATES; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; MICE; MODELS, MOLECULAR; NOOTROPIC AGENTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SCOPOLAMINE;

EID: 77956324497     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100573q     Document Type: Article

References (90)

1. Butters, N.; Delis, D. C.; Lucas, J. A. Clinical Assessment of Memory Disorders in Amnesia and Dementia Annu. Rev. Psychol. 1995, 46, 493-523
2. Cummings, J. L.; Doody, R.; Clark, C. Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention Neurology 2007, 69, 1622-1634
3. Giacobini, E. Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease Neurochem. Res. 2003, 28, 515-522
4. Terry, A. V.; Buccafusco, J. J. The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development J. Pharmacol. Exp. Ther. 2003, 306, 821-827
5. Bazelyansky, M.; Robey, E.; Kirsch, J. F. Fractional Diffusion-Limited Component of Reactions Catalyzed by Acetylcholinesterase Biochemistry 1986, 25, 125-130
6. Ballmaier, M.; Casamenti, F.; Scali, C.; Mazzoncini, R.; Zoli, M. Rivastigmine Antagonizes Deficits in Prepulse Inhibition Induced by Selective Immunolesioning of Cholinergic Neurons in Nucleus Basalis Magnocellularis Neuroscience 2002, 114, 91-98
7. Barnes, C. A.; Meltzer, J.; Houston, F.; Orr, G.; McGann, K. Chronic Treatment of Old Rats with Donepezil or Galantamine: Effects on Memory, Hippocampal Plasticity and Nicotinic Receptors Neuroscience 2000, 99, 17-23
8. Van Dam, D.; Abramowski, D.; Staufenbiel, M.; De Deyn, P. P. Symptomatic Effect of Donepezil, Rivastigmine, Galantamine and Memantine on Cognitive Deficits in the APP23 Model Psychopharmacology 2005, 180, 177-190
9. Clegg, A.; Bryant, J.; Nicholson, T.; McIntyre, L.; De Broe, S.; Gerard, K.; Waugh, N. Clinical and Cost-Effectiveness of Donepezil, Rivastigmine and Galantamine for Alzheimer's Disease: A Rapid and Systematic Review Health Technol. Assess. 2001, 5, 1-137
10. Clegg, A.; Bryant, J.; Nicholson, T.; McIntyre, L.; De Broe, S.; Gerard, K.; Waugh, N. Clinical and Cost-Effectiveness of Donepezil, Rivastigmine and Galantamine for Alzheimer's Disease Int. J. Technol. Assess. Health Care 2002, 18, 497-507
11. Goldlist, B.; Gordon, M.; Naglie, G. Galantamine vs Donepezil in the Treatment of Alzheimer's disease Drugs Aging 2003, 20, 1139-1140
12. Prasher, V. P. Review of Donepezil: Ageing and Health Issues in Intellectual Disabilities Int. J. Geriatr. Psychiatry 2004, 19, 509-515
13. Frantz, S. Drug Discovery: Playing Dirty Nature 2005, 437, 942-943
14. Van der Schyf, C. J.; Youdim, M. B. Multifunctional Drugs as Neurotherapeutics Neurotherapeutics 2009, 6, 1-3
15. Scarpini, E.; Scheltens, P.; Feldman, H. Tretament of Alzheimer's Disease: Current Status and New Perspectives Lancet Neurol. 2003, 2, 539-547
16. Tariot, P. N.; Federoff, H. J. Current treatment for Alzheimer disease and future prospects Alzheimer Dis. Assoc. Disord. 2003, 17 (Suppl 4) S105-S113
17. Aracava, Y.; Pereira, E. F. R.; Maelicke, A.; Albuquerque, E. X. Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently than N -methyl- d -aspartate Receptors in Rat Hippocampal Neurons J. Pharmacol. Exp. Ther. 2005, 312, 1195-1205
18. Banerjee, P.; Samoriski, G.; Gupta, S. Comments on "Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently than N -methyl- d -aspartate Receptors in Rat Hippocampal Neurons" J. Pharmacol. Exp. Ther. 2005, 313, 928-929
19. Ballmaier, M.; Casamenti, F.; Scali, C.; Mazzoncini, R.; Zoli, M. Rivastigmine Antagonizes Deficits in Prepulse Inhibition Induced by Selective Immunolesioning of Cholinergic Neurons in Nucleus Basalis Magnocellularis Neuroscience 2002, 114, 91-98
20. Barnes, C. A.; Meltzer, J.; Houston, F.; Orr, G.; McGann, K. Chronic Treatment of Old Rats with Donepezil or Galantamine: Effects on Memory, Hippocampal Plasticity and Nicotinic Receptors Neuroscience 2000, 99, 17-23
21. Van Dam, D.; Abramowski, D.; Staufenbiel, M.; De Deyn, P. P. Symptomatic Effect of Donepezil, Rivastigmine, Galantamine and Memantine on Cognitive Deficits in the APP23 Model Psychopharmacology (Berlin) 2005, 180, 177-190
22. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A. L, L. T.; Silman, I. Atomic Structure of Acetylcholinesterase from Torpedo californica: A Prototypic Acetylcholine-Binding Protein Science 1991, 253, 872-879
23. Tumiatti, V.; Milelli, A.; Minarini, A.; Rosini, M.; Bolognesi, M. L.; Micco, M.; Andrisano, V.; Bartolini, M.; Mancini, F.; Recanatini, M.; Cavalli, A.; Melchiorre, C. Structure-activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 4. Further Investigation on the Inner Spacer J. Med. Chem. 2008, 51, 7308-7312
24. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound Against Alzheimer's Disease J. Med. Chem. 2007, 50, 6446-6449
25. Hardy, J.; Selkoe, D. J. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics Science 2002, 297, 353-356
26. Ordentlich, A.; Barak, D.; Kronman, C.; Flashner, Y.; Leitner, M.; Segall, Y.; Ariel, N.; Cohen, S.; Velan, B.; Shafferman, A. Dissection of the Human Acetylcholinesterase Active Center Determinants of Substrate Specificity. Identification of Residues Constituting the Anionic Site, the Hydrophobic Site, and the Acyl Pocket J. Biol. Chem. 1993, 268, 17083-17095
27. Radic, Z.; Gibney, G.; Kawamoto, S.; MacPhee-Quigley, K.; Bongiorno, C.; Taylor, P. Expression of Recombinant Acetylcholinesterase in a Baculovirus System: Kinetic Properties of Glutamate 199 Mutants Biochemistry 1992, 31, 9760-9767
28. Amit, T.; Avramovich-Tirosh, Y.; Youdim, M. B.; Mandel, S. Targeting Multiple Alzheimer's Disease Etiologies with Multimodal Neuroprotective and Neurorestorative Iron Chelators FASEB J. 2008, 22, 1296-1305
29. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-Target-Directed Ligands to Combat Neurodegenerative Diseases J. Med. Chem. 2008, 51, 347-372
30. Soreq, H.; Seidman, S. Acetylcholinesterase: New Roles for an Old Actor Nature Rev. Neurosci. 2001, 2, 8-17
31. Johnson, G.; Moore, S. W. The Adhesion Function on Acetylcholinesterase is Located at the Peripheral Anionic Site Biochem. Biophys. Res. Commun. 1999, 258, 758-762
32. Giacobini, E. Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease Neurochem. Res. 2003, 28, 515-522
33. Munaz, F. J.; Aldunate, R.; Inestrosa, N. C. Peripheral Binding Site is Involved in the Neurotrophic Activity of Acetylcholinesterase NeuroReport 1999, 26, 3621-3625
34. Sharma, K. V.; Koenigsberger, C.; Brimijoin, S.; Gigbee, J. W. Direct Evidence for an Adhesive Function in the Noncholinergic Role of Acetylcholinesterase in Neurite Outgrowth J Neurosci. Res. 2001, 63, 165-175
35. Blasina, M. F.; Faria, A. C.; Gardino, P. F.; Hokoc, J. N.; Almeida, O. M.; de Mello, F. G.; Arruti, C.; Dajas, F. Evidence of Noncholinergic Function of Acetylcholinesterase During Development of Chicken Retina as Shown by Fasciculin Cell Tissue Res. 2000, 299, 173-184
36. Munoz-Torrero, D. Acetylcholinesterase Inhibitors as Disease Modifying Therapies for Alzheimer's Disease Curr. Med. Chem. 2008, 15, 2433-2455
37. Zhang, H. Y.; Yan, H.; Tang, X. C. Non-Cholinergic Effects of Huperzine A: Beyond Inhibition of Acetylcholinesterase Cell. Mol. Neurobiol. 2008, 28, 173-183
38. Inestrosa, N. C.; Alvarez, A.; Calderon, F. Acetylcholinesterase is a Senile Plaque Component that Promotes Assembly of Amyloid Beta-Peptide into Alzheimer's Filaments Mol. Psychiatry 1996, 1, 359-361
39. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A Structural Motif of Acetylcholinesterase that Promotes Amyloid Beta-Peptide Fibril Formation Biochemistry 2001, 40, 10447-10457
40. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. Amyloid Aggregation Induced by Human Acetylcholinesterase: Inhibition Studies Biochem. Pharmacol. 2003, 65, 407-416
41. Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity J. Med. Chem. 1994, 37, 4130-4146
42. Klebe, G.; Abraham, U. Comparative Molecular Similarity Index Analysis (CoMSIA) to Study Hydrogen-Bonding Properties and to Score Combinatorial Libraries J. Comput.-Aided Mol. Des. 1999, 13, 1-10
43. Catalyst, release version 4.1; Accelrys Inc.: San Diego, CA, 2006.
44. Chaudhaery, S. S.; Roy, K. K.; Saxena, A. K. Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase Inhibitors J. Chem. Inf. Model. 2009, 49, 1590-1601
45. Roy, K. K.; Dixit, A.; Saxena, A. K. An Investigation of Structurally Diverse Carbamates for Acetylcholinesterase (AChE) Inhibition Using 3D-QSAR Analysis J. Mol. Graphics Modell. 2008, 27, 197-208
46. Lopez-Rodriguez, M. L.; Benhamu, B.; de la Fuente, T.; Sanz, A.; Pardo, L. A Three-Dimensional Pharmacophore Model for 5-Hydroxytryptamine 6 (5-HT6) Receptor Antagonists J. Med. Chem. 2005, 48, 4216-4219
47. Güner, O.; Clement, O.; Kurogi, Y. Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances Curr. Med. Chem. 2004, 11, 2991-3005
48. Kim, H. -J.; Doddareddy, M. R.; Choo, H.; Cho, Y. S.; No, K. T.; Park, W. K.; Pae, A. N. New Serotonin 5-HT6 Ligands from Common Feature Pharmacophore Hypotheses J. Chem. Inf. Model. 2008, 48, 197-206
49. Riddle, D. L. C. elegans II; Cold Spring Harbor Laboratory Press: Plainview, NY, 1997.
50. Kaletta, T.; Hengartner, M. O. Finding function in novel targets: C. elegans as a model organism Nature Rev. Drug Discovery 2006, 5, 387-398
51. Sieburth, D.; Ch'ng, Q.; Dybbs, M.; Tavazoie, M.; Kennedy, S.; Wang, D.; Dupuy, D.; Rual, J. F.; Hill, D. E.; Vidal, M.; Ruvkun, G.; Kaplan, J. M. Systematic analysis of genes required for synapse structure and function Nature 2005, 436, 510-517
52. Mahoney, T. R.; Luo, S.; Nonet, M. L. Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarb-sensitivity assay Nature Protoc. 2006, 1, 1772-1777
53. Nguyen, M.; Alfonso, A.; Johnson, C. D.; Rand, J. B. Caenorhabditis elegans mutants resistant to inhibitors of acetylcholinesterase Genetics 1995, 140, 527-535
54. Debnath, A. K. Generation of Predictive Pharmacophore Models for CCR5 Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors J. Med. Chem. 2003, 46, 4501-4515
55. Hirashima, A.; Shigeta, Y.; Eiraku, T.; Kuwano, E. Inhibitors of Calling Behavior of Plodia interpunctella J. Insect Sci. 2003, 3, 4-13
56. Xu, Y.; Colletier, J. -P.; Weik, M.; Jiang, H.; Moult, J.; Silman, I.; Sussman, J. L. Flexibility of Aromatic Residues in the Active-Site Gorge of Acetylcholinesterase: X-ray versus Molecular Dynamics Biophys. J. 2008, 95, 2500-2511
57. Bar-On, P.; Millard, C. B.; Harel, M.; Dvir, H.; Enz, A.; Sussman, J. L.; Silman, I. Kinetic and Structural Studies on the Interaction of Cholinesterases with the Anti-Alzheimer Drug Rivastigmine Biochemistry 2002, 41, 3555-3564
58. Bartolucci, C.; Siotto, M.; Ghidini, E.; Amari, G.; Bolzoni, P. T.; Racchi, M.; Villetti, G.; Delcanale, M.; Lamba, D. Structural Determinants of Torpedo californica Acetylcholinesterase Inhibition by the Novel and Orally Active Carbamate Based Anti-Alzheimer Drug Ganstigmine (CHF-2819) J. Med. Chem. 2006, 49, 5051-5058
59. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
60. Greig, N. H.; De Micheli, E.; Holloway, H. W.; Yu, Q.-S.; Utsuki, T.; Perry, T. A.; Brossi, A.; Ingram, D. K.; Deutsch, J.; Lahiri, D. K.; Soncrant, T. T. The Experimental Alzheimer Drug Phenserine: Pharmacodynamics and Kinetics in the Rat Acta Neurol. Scand. 2000, 102, 74-84
61. Kamal, M. A.; Greig, N. H.; Alhomida, A. S.; Al-Jafari, A. A. Kinetics of Human Acetylcholinesterase Inhibition by the Novel Experimental Alzheimer Therapeutic Agent, Tolserine Biochem. Pharmacol. 2000, 60, 561-570
62. Brufani, M.; Filocamo, L.; Lappa, S.; Maggi, A. New Acetylcholinesterase Inhibitors Drugs Future 1997, 22, 397-410
63. Imbimbo, B. P.; Martelli, P.; Troetel, W. M.; Lucchelli, F.; Lucca, U.; Thal, L. J. Efficacy and Safety of Eptastigmine for the Treatment of Patients with Alzheimer's Disease Neurology 1999, 52, 700-708
64. Snape, M. F.; Misra, A.; Murray, T. K.; De Souza, R. J.; Williams, J. L.; Cross, A. J.; Green, A. R.A Comparative Study in Rats of the in Vitro and in Vivo Pharmacology of the Acetylcholinesterase Inhibitors Tacrine, Donepezil and NXX-066 Neuropharmacology 1999, 38, 181-93
65. Bolognesi, M. L.; Bartolini, M.; Cavalli, A.; Andrisano, V.; Rosini, M.; Minarini, A.; Melchiorre, C Design, Synthesis, and Biological Evaluation of Conformationally Restricted Rivastigmine Analogues J. Med. Chem. 2004, 47, 5945-5952
66. Trabace, L.; Cassano, T.; Steardo, L.; Pietra, C.; Villetti, G.; Kendrick, K. M.; Cuomo, V. Biochemical and Neurobehavioral Profile of CHF2819, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer's Disease J. Pharmacol. Exp. Ther. 2000, 294, 187-194
67. Smith, C. P.; Bores, G. M.; Petko, W.; Li, M.; Selk, D. E.; Rush, D. K.; Camacho, F.; Winslow, J. T.; Fishkin, R.; Cunningham, D. M.; Brooks, K. M.; Roehr, J.; Hartman, H. B.; Davis, L.; Vargas, H. M. Pharmacological Activity and Safety Profile of P10358, A Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer's Disease J. Pharmacol. Exp. Ther. 1997, 280, 710-720
68. Mustazza, C.; Borioni, A.; Giudice, M. R. D.; Gatta, F.; Ferretti, R.; Meneguz, A.; Volpe, M. T.; Lorenzini, P. Synthesis and Cholinesterase Activity of Phenylcarbamates Related to Rivastigmine, A Therapeutic Agent for Alzheimer's Disease Eur. J. Med. Chem. 2002, 37, 91-96
69. Decker, M. Acetylcholinesterase inhibitors based on carbamic acid quinolin-6-yl esters Expert Opin. Ther. Patents 2007, 17, 733-736
70. Shakya, N.; Fatima, Z.; Nath, C.; Saxena, A. K. Substituted Carbamic Acid Quinolin-6-yl Esters Useful as Acetylcholinesterase Inhibitors. U.S. Patent 0142335, June 2006.
71. Marsais, F; Bohn, P.; Fur, N. L.; Levacher, V. Heterocyclic Compounds, their Preparation and their Use as Medicaments, in Particular as Anti-Alzheimer Agents. U.S. Patent 062279, Mar 2009.
72. CombiGlide, version 2.5; Schrödinger, LLC: New York, 2009.
73. Schrödinger Software, version 8.0; Schrödinger, LLC: New York, 2005.
74. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Feather-Stone, R. M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity Biochem. Pharmacol. 1961, 7, 88-95
75. Brioni, J. D.; Hock, F. J.; McGaugh, J. J. Drug Effects on Learning and Memory. In, Drug Discovery and Evaluation: Pharmacological Assays; Vogel, G. H.; Vogel, W. H., Eds.; Springer Verlag: New York, 1997; pp 335-336.
76. Das, A.; Shankar, G.; Nath, C.; Pal, R.; Singh, S.; Singh, H. K. A Comparative Study in Rodents of Standardized Extracts of Bacopa Monniera and Ginkgo Biloba: Anticholinesterase and Cognitive Enhancing Activities Pharmacol., Biochem. Behav. 2002, 73, 893-900
77. Todeschini, R; Consonni, V. DRAGON Software, version 1.11; Milano Chemometrics and QSAR Research Group: Milano, Italy, 2001.
78. Accelrys Discovery Studio, version 2.0; Accelrys Inc.: San Diego, CA, 2007.
79. Yu, Q.-S.; Pei, X.-F.; Holloway, H. W.; Greig, N. H. Total Syntheses and Anticholinesterase Activities of (3aS)- N (8)-Norphysostigmine, (3aS)- N (8)-Norphenserine, Their Antipodal Isomers, and Other N (8)-Substituted Analogues J. Med. Chem. 1997, 40, 2895-2901
80. 8-Bisnorphysostigmine, Their Antipodal Isomers, and Other Potential Metabolites of Phenserine J. Med. Chem. 1998, 41, 2371-2379
81. Yu, Q.-S.; Holloway, H. W.; Utsuki, T.; Brossi, A.; Greig, N. H. Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Disease J. Med. Chem. 1999, 42, 1855-1861
82. Yu, Q.-S.; Holloway, H. W.; Utsuki, T.; Brossi, A.; Greig, N. H. Methyl Analogues of the Experimental Alzheimer Drug Phenserine: Synthesis and Structure-activity Relationships for Acetyl- and Butyrylcholinesterase Inhibitory Action J. Med. Chem. 2001, 44, 4062-4071
83. Luo, W.; Yu, Q.-S.; Zhan, M.; Parrish, D.; Deschamps, J. R.; Kulkarni, S. S.; Holloway, H. W.; Alley, G. M.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepine J. Med. Chem. 2005, 48, 986-994
84. Li, H.; Sutter, J.; Hoffman, R. HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. In Pharmacophore Perception, Development, and Use in Drug Design; Guner, O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 171-189.
85. 3-Adrenergic Receptor Agonism J. Comput.-Aided Mol. Des. 2005, 19, 93-110
86. Sprague, P. W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. In Perspectives in Drug Discovery and Design; Müller, K., Ed.; ESCOM Science Publishers BV: Leiden, The Netherlands, 1995; pp 1-21.
87. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMm: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations J. Comput. Chem. 1983, 4, 187-217
88. Sutter, J.; Güner, O. F.; Hoffman, R.; Li, H.; Waldman, M. Effect of Variable Weight and Tolerances on Predictive Model Generation. In Pharmacophore Perception, Development, and Use in Drug Design; Guner, O. F., Ed.; International University Line: La Jolla, CA, 1999; pp 501-511.
89. Brenner, S. The genetics of Caenorhabditis elegans Genetics 1974, 77, 71-94
90. Stiernagle, T. Maintenance of C. elegans. In C. elegans: A Practical Approach; Hope, I., Ed.; Oxford University Press: New York, 1999; pp 51-67.